Reports- Neuromyelitis Optica Drug Market | страница 3

1.2.3 Cost
1.3 Market Analysis by Applications
1.3.1 Acute attack
1.3.2 Remission prophylactic treatment
1.3.3
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA
1.4.1.2 Canada
1.4.1.3 Mexico
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany
1.4.2.2 France
1.4.2.3 UK
1.4.2.4 Russia
1.4.2.5 Italy
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China
1.4.3.2 Japan
1.4.3.3 Korea
1.4.3.4 India
1.4.3.5 Southeast Asia
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil
1.4.4.2 Egypt
1.4.4.3 Saudi Arabia
1.4.4.4 South Africa
1.4.4.5 Nigeria
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Neuromyelitis Optica Drug Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Pfizer Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share
2.2 FRESENIUS
2.2.1 Business Overview
2.2.2 Neuromyelitis Optica Drug Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 FRESENIUS Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market
Share
2.3 TEVA
2.3.1 Business Overview
2.3.2 Neuromyelitis Optica Drug Type and Applications
2.3.2.1 Type 1